Acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents

此次收购使Labcorp成为唯一一家在四大洲拥有全资实验室网络的中心实验室提供商

BURLINGTON, N.C.

北卡罗来纳州伯灵顿

,

，

Sept. 8, 2026

2026年9月8日

/PRNewswire/ --

/PRNewswire/ --

Labcorp

Labcorp

(NYSE:

（纽约证券交易所：

LH

左心室

), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed..

），作为创新且全面的实验室服务的全球领导者，今日宣布收购 MLM Medical Labs（MLM），这是一家领先的全球中心实验室和特殊实验室服务提供商，业务遍及美国、德国和南非。交易的财务条款未予披露。

The acquisition enhances Labcorp's position as a leading independent central laboratory services provider by expanding its presence in key clinical research regions and strengthening its biomarker and specialty testing capabilities. The transaction expands Labcorp's laboratory footprint and establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa.

此次收购通过扩大Labcorp在关键临床研究区域的布局，并增强其生物标志物和特殊检测能力，巩固了其作为领先独立中心实验室服务提供商的地位。该交易扩大了Labcorp的实验室网络覆盖范围，使其成为唯一一家在北美、欧洲、亚洲和非洲四大洲拥有全资实验室网络的中心实验室提供商。

The combination brings together Labcorp's global scale, breadth of scientific capabilities and operational infrastructure with MLM's established laboratory network and science-led service model..

此次合并将Labcorp的全球规模、广泛的科学能力与运营基础设施，与MLM成熟的实验室网络及以科学为主导的服务模式相结合。

'Clinical trial sponsors today need scientific expertise, global reach and operational flexibility to advance increasingly complex development programs,' said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. 'MLM complements Labcorp's existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies.

“如今的临床试验申办方需要科学专业知识、全球覆盖范围和运营灵活性，以推进日益复杂的开发项目。”Labcorp执行副总裁兼生物制药实验室服务总裁、首席医学与科学官Brian Caveney医学博士表示。“MLM补充了Labcorp现有的优势，并增强了我们支持各类规模申办方的能力，从新兴生物技术公司到领先制药企业。”

Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide.'.

我们携手具备提供赞助方所需能力、区域专长和高水准支持的优势，以推动创新疗法在全球的发展。

This integrated global infrastructure enhances Labcorp's ability to support complex multinational clinical trials with consistent scientific, operational and regulatory oversight from a single trusted partner. The acquisition also expands Labcorp's laboratory footprint in critical clinical research markets, including Africa, where MLM operates the continent's first fully CAP-accredited central laboratory..

这一整合的全球基础设施增强了Labcorp作为单一可信赖合作伙伴，通过一致的科学、运营和监管监督支持复杂跨国临床试验的能力。此次收购还扩大了Labcorp在关键临床研究市场的实验室布局，包括非洲地区，其中MLM运营着非洲大陆首家完全获得CAP认证的中央实验室。

In addition, the acquisition strengthens Labcorp's scientific and regulatory expertise and broadens access to biomarker and specialty testing capabilities that support increasingly complex clinical development programs.

此外，此次收购增强了Labcorp在科学和监管方面的专业知识，并扩大了其在生物标志物和专项检测能力方面的资源，以支持日益复杂的临床开发项目。

This acquisition reflects Labcorp's ongoing commitment to investing in central laboratory services and meeting the evolving needs of clinical trial sponsors worldwide.

此次收购体现了Labcorp对持续投资中心实验室服务、满足全球临床试验申办方不断变化的需求的坚定承诺。

Evercore served as exclusive financial advisor to Labcorp and Pierson Ferdinand and Hogan Lovells served as Labcorp's legal counsel.

Evercore 担任 Labcorp 的独家财务顾问，Pierson Ferdinand 和 Hogan Lovells 担任 Labcorp 的法律顾问。

About Labcorp

关于Labcorp

Labcorp (NYSE:

Labcorp（纽约证券交易所：

LH

左翼

) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities.

) 是全球创新且全面的实验室服务领导者，帮助医生、医院、制药公司、研究人员和患者做出清晰而自信的决策。我们凭借无与伦比的诊断和药物研发实验室能力，提供洞察并推动科学进步，以改善健康、提升生活质量。

The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at .

该公司近71,000名员工为约100个国家的客户提供服务，为2025年美国食品药品监督管理局（FDA）批准的新药和治疗产品中超过85%提供了支持，并为全球患者进行了超过7.5亿次检测。了解更多请访问。

www.labcorp.com

www.labcorp.com

.

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This press release contains forward-looking statements, including, but not limited to, statements with respect to the acquisition of MLM Medical Labs and how its capabilities are anticipated to benefit clinical trial sponsors.

本新闻稿包含前瞻性陈述，包括但不限于关于收购MLM Medical Labs以及其能力预计将如何惠及临床试验赞助商的陈述。

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements.

每项前瞻性陈述均可能因各种重要因素而发生变化，其中许多因素超出公司的控制范围。在某些情况下，这些因素已经影响了公司实施其业务战略的能力，并在未来（与其他因素一起）可能继续影响该能力，因此实际结果可能与这些前瞻性陈述所暗示的结果存在重大差异。

As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements..

因此，提醒读者不要过度依赖任何前瞻性陈述。

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC.

即使公司的预期发生变化，公司也没有义务对这些前瞻性陈述进行任何更新。所有前瞻性陈述均受本警示性声明的明确限定，其全部内容均以本声明为准。有关可能影响经营和财务结果的潜在因素、风险和不确定性的更多信息，请参阅公司最新提交的10-K表格年度报告中“风险因素”标题下的内容，以及公司向美国证券交易委员会（SEC）提交的其他文件。

The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading 'MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.'.

阅读本新闻稿中的信息时，应结合审查公司向美国证券交易委员会（SEC）提交的文件，包括公司最新提交的10-K表年度报告中“管理层对财务状况和经营成果的讨论与分析”标题下的信息。

SOURCE Labcorp

来源：Labcorp

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示